FDA: Treatment with angiotensin receptor blockers for high blood pressure does not increase risk of cancer

The U.S. Food and Drug Administration today announced that a group of medications used to control high blood pressure, called angiotensin receptor blockers (ARBs), do not increase the risk of developing cancer in patients using the medications.